SCHEMBL4358102

SCHEMBL4358102

Cc1cc(OCC(=O)N(C)C2CCN(CC(=O)Nc3cccc(Cl)c3C)CC2)c(C)c(C)c1N

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 3/20 0.49
▸ DRD3 P35462 3/20 0.49
▸ SIGMAR1 Q99720 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ HTT P42858 2/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ TMEM97 Q5BJF2 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ POLB P06746 2/20 0.42
▸ LMNA P02545 3/20 0.42
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13928729 0.90 SMN1; SMN2 (0.46) SMN1; SMN2CYP2D6CYP2C19NPSR1POLB
SCHEMBL4202948 0.88 MEN1 (0.38) DRD4DRD3SIGMAR1MAPTSMN1; SMN2
SCHEMBL4205168 0.88 ALDH1A1 (0.45) DRD4DRD3CYP2D6NPSR1HSD17B10
SCHEMBL4205213 0.86 POLB (0.40) DRD4SMN1; SMN2HTTCYP2D6CYP2C9
SCHEMBL4212200 0.86 KCNA5 (0.46) DRD4DRD3MAPTSMN1; SMN2HTT
SCHEMBL13928731 0.86 DRD4 (0.49) DRD4DRD3SIGMAR1MAPTSMN1; SMN2
SCHEMBL4212892 0.85 ALDH1A1 (0.39) DRD4SMN1; SMN2NPSR1HSD17B10POLB
SCHEMBL4212566 0.84 RAD52 (0.38) DRD4SMN1; SMN2HTTCYP2D6CYP2C19
SCHEMBL13928735 0.81 POLB (0.42) SMN1; SMN2CYP2C19NPSR1POLBLMNA
SCHEMBL4218431 0.80 POLB (0.47) SMN1; SMN2NPSR1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488738-B2 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof ASUBIO PHARMA CO., LTD. (JP) 2009-02-10 — — US disclosed
US-7488738-B2 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof ASUBIO PHARMA CO., LTD. (JP) 2009-02-10 — — US disclosed
US-7488738-B2 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof ASUBIO PHARMA CO., LTD. (JP) 2009-02-10 — — US disclosed
US-6998401-B2 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof SUNTORY LIMITED (JP) 2006-02-14 — — US disclosed
US-20050245574-A1 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-11-03 — — US disclosed
EP-1045693-B1 AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS DAIICHI SUNTORY PHARMA CO LTD (JP) 2004-06-30 — — EP disclosed
US-20040063748-A1 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof ASUBIO PHARMA CO., LTD. (JP) 2004-04-01 — — US disclosed
US-6559146-B1 Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins SUNTORY LIMITED (JP) 2003-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245574-A1 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof CAMK2A, CAMK2B, SLC1A2 DRD4 1044/4885DRD3 532/4885SIGMAR1 885/4885
US-20040063748-A1 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof FABP7, SLC1A2, CAMK2A DRD4 967/4885DRD3 409/4885SIGMAR1 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback